The integrity of the vasculature plays an important role in the success of allogeneic organ and haematopoietic stem cell transplantation. Endothelial cells (EC) have previously been shown to be the target of activated cytotoxic T lymphocytes (CTL) resulting in extensive cell lysis. Mesenchymal stromal cells (MSC) are multipotent cells which can be isolated from multiple sites, each demonstrating immunomodulatory capabilities. They are explored herein for their potential to protect EC from CTL-targeted lysis. CD8 + T cells isolated from human PBMC were stimulated with mitotically inactive cells of a human microvascular endothelial cell line (CDC/EU.HMEC-1, further referred to as HMEC) for 7 days. Target HMEC were cultured in the presence or absence of MSC for 24 h before exposure to activated allogeneic CTL for 4 h. EC were then analysed for cytotoxic lysis by flow cytometry. Culture of HMEC with MSC in the efferent immune phase (24 h before the assay) led to a decrease in HMEC lysis. This lysis was determined to be MHC Class I restricted linked and further analysis suggested that MSC contact is important in abrogation of lysis, as protection is reduced where MSC are separated in transwell experiments. The efficacy of multiple sources of MSC was also confirmed, and the collaborative effect of MSC and the endothelium protective drug defibrotide were determined, with defibrotide enhancing the protection provided by MSC. These results support the use of MSC as an adjuvant cellular therapeutic in transplant medicine, alone or in conjunction with EC protective agents such as defibrotide.
Introduction
Allogeneic transplantation of organs or haematopoietic stem cells is often the only therapeutic option for end-stage organ disease or leukaemia, respectively. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, requiring immunosuppression. Unfortunately, immunosuppression seriously affects the quality of life of patients and is a major threat to the health economy. The vascular endothelium is the primary contact between foreign and self, and damage to vascular endothelial cells represents the primary adverse event finally resulting in loss of organ function. This central role and early appearance of endothelial damage makes it an ideal target for early therapeutic intervention. Endothelial damage to the graft from ischaemic reperfusion injury in the case of solid organ transplantation [1] or to the host from conditioning in allogeneic haematopoietic stem cell transplantation [2, 3] ultimately leads to loss of organ function and transplant failure. Damage to the mucosal barriers results in the expression of damage associated molecular patterns and the translocation of foreign antigen such as LPS across damaged membranes. This combined with the exposure to inflammatory mediators results in the development of an immunologically active state, rendering EC to become antigen-presenting cells. Previous work published by our group demonstrated the destructive repercussions of the invasion of cytotoxic T lymphocytes (CTL) which specifically target endothelial cells (EC) [4] . Importantly, these CTL show an unusual phenotype (CD28-negative) and are peculiarly enhanced in their cytotoxic activity by the co-culture with FoxP3 + regulatory T cells (Treg cells) [4] , suggesting that the currently available immunomodulatory mechanisms cannot protect EC against these effector cells.
Over the last 10 years, the clinical use of bone marrowderived mesenchymal stromal cells (BM-MSC) as a cellular therapeutic has risen dramatically, with over 350 clinical trials registered across a broad spectrum of diseases [5] .
Early work looked at MSC for their capacity to differentiate into multiple lineages [6, 7] , testing their ability to replace damaged tissue by in situ differentiation. It is now, however, more commonly suggested that MSC home to the site of injury and influence the local environment through the release of soluble factors [8, 9] . The same can be observed in vascular biology where soluble mediators, such as VEGF and IGF, released by MSC in a model of myocardial infarction promote tube formation and protect cardiac cells against apoptosis [10] . Bader et al. [11] also showed that MSC can protect EC from apoptosis in hypoxic conditions associated with ischaemic disease, improving viability and proliferation. These results support the use of MSC in transplant medicine, targeting protection or repair of the endothelium. Use of MSC in combination therapy has also become common practice, with publications into renal fibrosis [12] and clinical trials in GvHD [13] , siting increased attenuation of pathology.
Defibrotide is a polydisperse mixture of mostly single stranded oligonucleotides with anti-inflammatory, antiischaemic, pro-fibrinolytic and antithrombotic functions [14] . It has been approved by the European Medicines Agency (2013) as well as the US Food and Drug Administration (2016) as a treatment for hepatic venoocclusive disease (VOD), a severe endothelial complication following allogeneic haematopoietic stem cell transplantation. Treatment of EC with the chemotherapeutic drug fludarabine, also used in pretransplant conditioning, results in apoptosis and allogeneic activation. The addition of defibrotide rescued EC from these adverse events without interfering with the desirable antileukaemic and anti-T cell proliferative effects of the drug [15] . These observations prompted investigation into not only the efficacy of MSC, but also the examination of defibrotide and MSC as a combination therapy in a cytotoxicity assay.
Materials and methods
Cell culture and reagents. The human dermal microvascular endothelial cell line CDC/EU.HMEC-1 (further referred to as HMEC) was kindly provided by the Centers for Disease Control and Prevention (Atlanta, Georgia, USA) [16] . HMEC were cultured in MCDB131 medium, supplemented with 15% foetal calf serum (FCS), 1 lg/ml hydrocortisone (Sigma, Deisenhofen, Germany), 10 ng/ml epidermal growth factor (Collaborative Biochemical Products, Bedford, MA, USA) and antibiotics. Defibrotide was kindly provided by Dr. Terenzio Ignoni (Gentium, SpA., a Jazz Pharmaceuticals Company, Villa Guardia (CO), Italy). Bone marrow-derived MSC (BM-MSC) were provided by Apceth GmbH & Co.KG, by the Department of Internal Medicine III, Regensburg University Medical Centre, Regensburg, Germany, or purchased from Pelobiotech (PELOBiotech GmbH, Planegg, Germany); perivascular mesenchymal stem cells (PVSC) were isolated from the perivascular region of umbilical cord arteries [Department of Gynaecology, Wolfart-Klinik (Gr€ afelfing, Germany)]; and amniotic membrane-derived MSC (hAMSC) were kindly provided by Prof. Ornella Parolini, Centro di Ricerca E. Menni, Fondazione Poliambulanza, Brescia, Italy. MSC used in this study were characterized according to the standardised guidelines agreed upon by the International Society for Cellular Therapy [17] . All MSC were used in passages 3-6 only. For each experiment, 2.5 9 10 6 endothelial cells were incubated with 0.5 9 10 6 MSC (ratio 5:1) in the presence of descending concentrations of T cells. HH7 heart explant cells were provided by the department of cardiac surgery (Munich University, Germany) and cultured in RPMI medium supplemented with 10% foetal calf serum (FCS), 1% Lglutamine and 1% penicillin/streptomycin. All MSC were cultured in Human Xeno-free Mesenchymal Stem Cell Medium (PELOBiotech GmbH) containing supplement and 1% penicillin/streptomycin. T lymphocytes were isolated form PBMC from either leukapheresis products by the Department of Clinical Chemistry and Transfusion Medicine (Regensburg University Medical Centre) or from buffy coats by the Irish Blood Transfusion Service and were cultured in RPMI containing 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin and 300 U/ml of interleukin 2 (IL-2);(Novartis, Basel, Switzerland). All reagents have been purchased from Life Technologies unless stated otherwise. All biological samples were obtained with informed consent according to guidelines of the local ethical review committees.
Separation and culture of CD8 T cells. CD8 + T cells were isolated using MagCellect CD8 + T cell isolation kit according to manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). Briefly, PBMC were negatively selected by incubation with biotin antibody cocktail followed by incubation with ferro-streptavidin and finally magnetic separation. Purity of isolation was always determined by flow cytometric analysis (antibody combinations of CD3/4, CD3/8, CD3/56 and CD14/45, respectively), showing >98% of the isolated cells CD8+ and the complete absence of CD4 (T cells), CD14 (antigen-presenting cells) and NK cells (data not shown).
Cytotoxicity assay. CD8 + T cells were stimulated in a ratio of 1:1 with mitotically inactivated (50 lM silibinin, Sigma-Aldrich, Deisenhofen, Germany) HMEC for 7 days in the presence of IL-2 (300 U/ml). Cytotoxicity was assessed according to a well-established protocol, first described by Piriou et al. [18] . Target HMEC were labelled with 30 lM 3,3 0 -dioctadecyloxacarbocyanine perchlorate (DIOC18 (3) ), a fluorescent lipophilic tracer, by incubating at 37°C for 15 min. It had been shown by these authors that DIOC18 (3) , the dye used for labelling the target cells, is stable and does not leak out of the target cells, that is it does not stain effector cells or other cells in the system [18] .
HMEC were then cultured in the presence or absence of MSC or drugs (day-1) for 24 h followed by incubation with CD8 + T cells at descending effector to target ratios (20:1, 10:1 and 5:1) for another 4 h. The percentage of specific lysis determined by counter staining the HMEC with propidium iodide (PI)(0.2 lg/ml, Sigma-Aldrich, Deisenhofen, Germany) and determining lysis by flow cytometry analysis (BD, Oxford, UK). Defibrotide was added to the culture system at day 1 at a concentration of 25 lM, indomethacin (Sigma-Aldrich, Deisenhofen, Germany) was used at a concentration of 40 lM, and w6/32 was also added at day 1. w6/32 hybridoma supernatants were obtained from cells that had been purchased from ATCC (Manassas, VA, USA) and were used at a ratio of 1:5 and 1:10. Of note, it is in the nature of the assay that the overall level of cytotoxicity varies among experimental groups, mainly depending on which CD8+ T cell donor is used, and which level of co-stimulatory molecules the donor cells show in the particular experiment.
Transwell culture. Transwell inserts for a 24-well plate with a 0.4-lm pore size (Corning, Hazebrouck, France) were used to separate the MSC from HMEC and CTL during the cytotoxicity assay. 5 9 10 4 DIOC18 (3)-labelled HMEC were seeded in the bottom of the 24-well plate, while 1 9 10 4 BM-MSC were plated either in contact with the HMEC or in the upper chamber of the transwell insert. The cells were cultured for 24 h in HMEC medium. The medium was removed and replaced with CTL medium before CTL were added to the bottom well of the plates and cultured for a further 4 h. The HMEC were collected and counter stained with PI and examined by flow cytometry.
PGE ELISA. The amount of PGE-2 produced during a cytotoxicity assay was measured using a commercially available ELISA Kit from Cayman Chemical (Ann Arbour, MI, USA). The PGE-2 assay is based on the competition between PGE-2 and PGE-2 acetylcholinesterase (AChE) conjugate (PGE-2 tracer) for a limited amount of PGE-2 monoclonal antibody. ELISA were carried out according to manufacturer's instructions. The microplate (96-well polystyrene) was precoated with goat anti-mouse polyclonal antibody. The standards and samples in triplicate and controls in duplicate (50 ll) were added to the plate and read at an absorbance of 405 nm using a multiscan plate reader (LabSystems, Thermo-Fisher, Waltham, MA, USA).
Statistical analysis. Statistical analysis was performed using GraphPad PrismTM software (GraphPad, San Diego, CA, USA). The students paired t-test was used when statistical analysis was required between two experimental groups. One-way ANOVA was used to test for statistical significance of differences when multiple experimental groups were compared. Data are presented as the AE standard error of the mean (SEM). P-values of P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) were considered statistically significant.
Results

Mesenchymal stromal cells protect endothelial cells against allogeneic CD8
+ CTL
Previous data published by our group demonstrated the existence of a strictly EC-specific CD8 + T cell subpopulation that is peculiarly enhanced in their cytotoxic activity towards endothelial cells by the co-administration of Treg cells [4] . Following up on this work, this study looked to investigate the role of MSC in protecting EC from targeted killing. Untouched CD8 + T cells were isolated and co-cultured with allogenic EC (HMEC) for 7 days. Twenty-four hours before the cytotoxicity assay, HMEC were stained with DIOC and cultured in the presence or absence of BM-MSC at a ratio of 5:1. The cytotoxicity assay involves culturing the primed CTL with the treated or untreated HMEC for 4 h, staining with PI and analysing the expression of PI versus DIOC by flow cytometry. When cultured in the presence of BM-MSC, there was a significant decrease in the extent of cell lysis elicited by the CTL. The CTL were titrated resulting in a titrated rate of cell death; in each case, the MSC reduced the extent of EC killing (Fig. 1A) , with significance at 20:1 graphed as a bar chart (Fig. 1B) , with the 10:1 and 5:1 ratios also reaching significance (data not shown).
Mesenchymal stromal cells protection requires contact
Following on from this work, efforts were made to determine the signalling mechanisms involved in MSC protection of EC. However, before this could be achieved more needed to be understood about the physical interactions between the cells in culture. The lysis of EC by CTL was herein shown to be fully MHC Class I-linked, as pretreatment of HMEC with w6/32, a neutralizing MHC Class I-linked monoclonal antibody [19, 20] , prior to their encounter with CTL, completely abrogated the CTL activity. The extent of lysis was reduced to that observed with MSC co-culture ( Fig. 2A) . Secondly, to eliminate the possibility that MSC were simply masking the contact sites on EC from the CTL by physically covering them, human heart explant cells (HH7) as size-matched negative controls were used in the place of MSC in a cytotoxicity assay. These heart explant cells failed to protect the EC from cell death thus negating the possibility of MSC simply shrouding the EC (Fig. 2B) .
MSC signalling has provoked a long-running debate as to the importance of cell-cell contact over the release of soluble factors. Results from transwell cytotoxicity experiments performed herein showed that in the absence of cell contact MSC failed to protect HMEC from CTL-induced lysis (Fig 2C) . The extent of HMEC lysis did not increase to levels observed in untreated HMEC however suggesting that MSC may release some soluble factor that infers some modicum of protection but not to the extent of MSC in contact conditions. In an effort to delve deeper into the signalling pathway involved in MSC protection a cytokine array containing over 100 different targets was performed on the supernatant from transwell experiments ( Figure S1 ). There was little difference between the supernatant from MSC in contact and those in transwell to suggest a candidate for signalling, and there were differences between some of the chemokines tested but mainly in the chemokine family, while interesting in terms of lymphocyte infiltration, they were not deemed relevant to the signalling pathways between MSC and EC. However, when PGE2 was examined by competitive ELISA, there was a drop in the level of PGE in the supernatant of cells from the transwell group (Fig. 2B) . 4 HMEC were seeded in a 24-well plate, and 1 9 10 4 BM-MSC were added to the culture either in contact with the HMEC or in a transwell chamber and cultured for 24 h (C). Targets were analysed for lysis as described in figure legend 1. Results from multiple experiments were graphed using data from the 20:1 ratio groups. n = 3, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. ............................................................................................................................................................ ...
Protection evident in mesenchymal stromal cells from multiple sources
Bone marrow-derived mesenchymal stromal cells is one of the most commonly used and studied groups of stem cells predominantly due to the ease of isolation and their initial beneficial use in autologous MSC therapy. However, MSC isolated from the umbilical cord and placenta have been shown to be less immunogenic than BM-MSC while maintaining the same modulatory abilities [21] . To determine whether MSC from different sources would work as well in this system, MSC from the perivascular region of umbilical cord arteries (PVSC) and MSC of the amniotic membrane (hAMSC) were tested in a cytotoxicity assay with various CTL donors. Although BM-MSC provide the greatest protection on HMEC with only 24% of the cell population undergoing lysis, PVSC (38%) and hAMSC (37%) still significantly reduce the level of CTL lysis (Fig. 3) .
Defibrotide enhances the protective effect of mesenchymal stromal cells
Combination therapy, particularly in the case of cellular therapy, has received a lot of attention in the last number of years. Defibrotide as described above has been tested successful in the treatment of VOD, and its known interaction with endothelial cells led to a study of the drug in the stabilization of the endothelial compartment [22] . Previously published work from our group defined a role for defibrotide in protecting the endothelium form CTL-targeted lysis without interfering with the regular growth and function of the cells [15] . This study sought to determine whether defibrotide, given in combination with MSC, would increase the protection achieved by the MSC alone. In line with previous findings, MSC decreased the lysis of EC, notably; however, the addition of defibrotide further increased the extent of inhibition, adding to the abrogation of lysis achieved by MSC alone (Fig. 4 ).
Discussion
The current study sought to examine the role of MSC in the protection of EC from CTL-induced lysis. Herein, we have shown that MSC from multiple sources, not only bone marrow, can abrogate EC cytotoxicity and work cooperatively with defibrotide to prevent EC death. Although the exact signalling pathway for MSC protection was not discovered, this study has provided much insight into the characteristics of the cellular interactions while also supporting the possibility of prostaglandins as potential mediators. To our knowledge, these findings are the first of their kind, establishing a role for MSC protection of EC from CTL killing.
Mesenchymal stromal cells influence over vascular cells has been studied in depth; in most cases, their efficacy is demonstrated in models of vascular pathophysiological diseases [10, 11, 23] . Although much is yet unknown about their mechanism of action, many such studies agree that the health of the endothelium is a major factor in the pathogeneses of vascular diseases [24] and organ failure [3] . Previous work by our group into the role of CTL in EC Figure 3 Co-culture of HMEC with multiple sources of MSC result in protection from CTL lysis. CTL were cultured with HMEC for 7 days. At day 1, HMEC were co-cultured in the presence or absence of bone marrow mesenchymal stromal cells (BM-MSC), perivascular region of umbilical cord arteries (PVSC) or MSC of the amniotic membrane (hAMSC) at a ratio of 5:1, respectively, for 24 h. Targets were analysed for lysis as described in figure legend 1. Data from 4 independent experiments with 4 different PBMC donors. *P ≤ 0.05. Figure 4 Defibrotide adds to the protective effect of MSC. CTL were cultured with HMEC for 7 days. At day 1, HMEC were co-cultured in the presence or absence of BM-MSC at a ratio of 5:1, with or without the addition of defibrotide (25 lM) for 24 h. Targets were analysed for lysis as described in figure legend 1. Results from multiple experiments were graphed using data from the 20:1 ratio groups. n = 3, *P ≤ 0.05, **P ≤ 0.01. [4] . This was an important discovery as Treg cells are commonly studied as a potential cellular therapeutic in the treatment of GvHD [25] . Following on from this work, MSC were examined herein for their ability to abrogate the MHC Class I-linked lysis of EC by CTL. There are two possible routes for MSC to function in this system, through interaction with the HMEC 24 h prior to the cytotoxicity assay or through their interaction with the CTL during the cytotoxicity assay. Size exclusion assays using heart explant cells, similar in size to MSC, eliminated the possibility that the MSC were simply masking the HMEC and thus interaction sites, while animal studies, such as that by Togel et al., demonstrate how the release of trophic mediators by MSC has a protective and regenerative effect on EC [23] . In the context of MSC inhibition of CTL, in vitro studies have concluded that MSC inhibit the proliferation and cytotoxicity of CTL [26] without themselves being susceptible to CTL killing [27] . Given the short exposure time between the MSC and CTL, it stands to reason that the MSC directly affect the EC. It is interesting to note that cell-to-cell contact between EC and MSC is required for their full protective efficacy, which is in contrast to studies with mixed lymphocyte cultures (MLR) where MSC could inhibit T cell proliferation even in a transwell system [28, 29] . However, as with the MLR, evidence from transwell studies herein as well as significant differences in the MSC supernatant in the presence or absence of cell contact suggest a role for prostaglandins in EC protection [29, 30] . Interestingly, the levels of PGE2 were diminished when MSC were separated by transwell but when MSC were left in contact with only the CTL, levels of PGE2 increased. One hypothesis to explain these results is that of licensing. MSC are known to react to the local milieu, a characteristic elegantly described by Tobin et al. where in the absence of prior licensing, MSC failed to improve the outcome of in vivo GvHD following early administration [31] . In this instance, the interaction between MSC and CTL may trigger an increase in PGE2 production resulting in protection of EC. This hypothesis is further supported by the fact that MSC in transwell experiments failed to achieve the same level of inhibition. Of note, it is not finally determined which cell type is actually producing PGE2. However, previous studies by the authors' laboratory and other investigators with MLR strongly suggest that MSC are the source of PGE2. In enzyme-linked immunosorbent assays (ELISA), with allogeneic MLR in the presence or absence of MSC, only supernatants with MSC produced PGE2 [28, 29] . The clear abrogation of EC lysis by MSC demonstrated in this study suggests that future adjuvant therapies may look to MSC as an additional treatment option for solid organ rejection and GvHD, particularly in cases where the endothelium is the therapeutic target and Treg cell treatment would be unsuitable. The cooperative relationship between MSC and the endothelial stabilizing drug defibrotide demonstrated herein speaks to their capacity as a potential prophylactic treatment in host conditioning or organ transplantation. This study has also shown that the source of MSC does not alter the protection provided. MSC from placental sources have even been shown to present higher immunomodulatory capacity than those isolated from the bone marrow. In 2012, Rossi et al. [30] elegantly demonstrated how amnion-derived cells exhibit superior immunomodulatory capacity by comparing the conditioned medium (CM) from these cells to that of BM-MSC. Where direct cell contact by both hAMTC and BM-MSC resulted in immunosuppression, only the hAMTC could achieve suppression through the use of conditioned medium alone. Prevention is always better than cure; we have shown that MSC therapy protects the endothelium from targeted lysis, and if used in conjunction with defibrotide could improve endothelial health, reducing the risk of graft rejection. The health of the endothelium is key to the success of transplant medicine, and MSC are demonstrated herein to offer a tangible means of preventing EC lysis from allogenic immune cells.
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Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 Cytokine array of supernatant from transwell cytotoxicity assay. CTL were cultured with HMEC for 7 days. At day 1, 5 9 10 4 HMEC were seeded in a 24-well plate, 1 9 10 4 BM-MSC were added to the culture either in contact with the HMEC or in a transwell chamber. The cells were cultured for 24 h before addition of CTL to the 24-well plate, always in the lower chamber, in contact with the HMEC. Supernatant was collected and run through a cytokine array as described in materials and methods. Results were graphed according to pixel density as determined by ImageJ software analysis. Figure S2 Production of PGE2 in transwell cytotoxicity assay. Supernatant tested in the PGE2 EIA assay was collected as described in Supp. Fig 1 and analysed according to the manufactures' protocol described in materials and methods.
